TP和MVP方案治疗非小细胞肺癌72例临床分析

目的评价MVP（MMC＋VDS＋PDD）与TP（Paelilaxel＋PDD）2种化疗方案治疗中晚非小细胞肺癌的疗效。方法72例中晚期非小细胞肺癌患者分为2组，MVP组37例，MMC（丝裂霉索）6—8mg／m^2，静脉推注，d1；Vindesine（长春地辛）2｀3mg／m^2，静脉滴注。d1，d8；PDD70～80mg／m^2，静脉滴注，d1。TP组35例，Paclitaxel（紫杉醇）170～180mg／m^2，静脉滴注。d1；PDD70—80mg／m^2。静脉滴注，d1。每3—4周为1周期，连用2～3周期。结果MVP及TP组有效率分别为27．0％与42．9％。主要不良反应MVP组为骨髓抑制及恶心、呕吐；TP组为骨髓抑制、恶心呕吐及脱发。结论MVP及TP化疗方案在治疗中晚期非小细胞肺癌的有效率统计学上无显著差异，毒性可耐受。

Clinical analysis of TP and MVP regimens in the treatment of 72 patients with non-small cell lung cancer

Objective To evaluate the efficacy and toxicity of combination chemotherapy of Mitomycin plus Vindesine and Cisplatin,Paclitaxel plus Cisplatin in the treatment of advanced non-small cell lung cancer.Methods Seventy-two patients with non-small cell lung cancer were enrolled.Thirty-seven patients received MVP(Mitomycin 6~8 mg/m~2,day 1,Vindesine 2~3 mg/m~2,day 1,8 and Cisplatin 70~80 mg/m~2 day 1).Thirty-five patients received TP(Paclitaxel 170~180 mg/m~2,day 1 and Cisplatin 70~80 mg/m~2,day 1).It lasted for tow or three cycles.Results The objective response rate was 27.0% in the MVP arm and 42.9% in the TP arm.The main side effects were myelosuppression,nausea,vomiting on the MVP arm and myelosuppression,nausea,vomiting,shed on the TP arm.Conclusions There is not significant difference in response rate between the MVP and TP regimens.The side effects are tolerable.